Interleukin-6 expression contributes to lapatinib resistance through maintenance of stemness property in HER2-positive breast cancer cells

Lapatinib is an inhibitor of human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-25% of breast cancers. Clinically, lapatinib has shown promising benefits for HER2-positive breast cancer patients; however, patients eventually acquire resistance, limiting its long-term use....

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Wei-Chien, Hung, Chao-Ming, Wei, Ching-Ting, Chen, Tsung-Ming, Chien, Pei-Hsuan, Pan, Hsiao-Lin, Lin, Yueh-Ming, Chen, Yun-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308732/
https://www.ncbi.nlm.nih.gov/pubmed/27694691
http://dx.doi.org/10.18632/oncotarget.11471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308732/
https://www.ncbi.nlm.nih.gov/pubmed/27694691
http://dx.doi.org/10.18632/oncotarget.11471

Ejemplares similares